Physician Resources
New Products/Product News
Am J Orthop. 2009 August;38(8):422-423
| Cayenne Medical, Inc., has announced the commercial launch of its CrossFix™ System for the repair of meniscal tears. The CrossFix™ system offers surgeons the benefits of both open suturing and arthroscopic meniscal repair. Cayenne Medical notes that the technology replicates results from “gold standard” open suturing techniques but through a faster and less invasive all-inside method. Unlike traditional all-inside meniscal repair devices, the CrossFix™ system leaves no plastic implants behind. The CrossFix™ system is a suture-only device that creates a 3-mm mattress stitch for an all-inside meniscal repair. The dual-needle design instantly deploys a horizontal or vertical mattress with a pre-tied sliding knot through a single insertion into the meniscus. The device includes an incorporated cannula and depth limiter that controls needle penetration, reducing the risk of neurovascular injury. The repair is biomechanically strong with pull-out forces equal to open suture techniques.* The company notes that the CrossFix™ system is fast and easy to use, offering surgeons reliable and reproducible patient outcomes. In addition to the statistically significant benefit in pain success at 3 months and function success at 24 months, the CORTOSS population experienced measurable benefits over the PMMA cohort in the following outcomes: A 43.4% reduction in subsequent, adjacent-level fractures in CORTOSS patients treated for a primary fracture at one level, as measured at the end of the 24-month follow-up period. There was 83% follow-up at the 24-month time point. This study, in combination with various clinical trials previously completed in the United States and Europe, brings the total number of patients studied for CORTOSS in vertebral compression fractures to 527. For more information, contact Cayenne Medical, Inc. * Data on file. |
Arthrodesis System
Integra LifeSciences Holdings Corporation announced it has received 510(k)
clearance from the US Food and Drug Administration (FDA) for the HALLU®-LOCK
MTP Arthrodesis System. The HALLU®-LOCK System features Surfix® Locking
Technology and is an upgrade of the HALLU®-FIX System. Surfix® Locking Technology
allows the surgeon to place the plate at the optimal distance from the bone and
then lock the screws.
The HALLU®-LOCK System is indicated for use in fixation of fractures, osteotomies,
or arthrodesis of the first metatarsophalangeal joint, including cases of hallux rigidus,
severe hallux valgus, and deformity caused from rheumatoid arthritis.
The HALLU®-LOCK MTP Arthrodesis System will be sold by Integra’s Extremity
Reconstruction sales organization, which focuses on lower-extremity fixation,
upper-extremity fixation, tendon protection, peripheral nerve repair/protection,
and wound repair.
For more information, contact